GRI Bio Inc
NASDAQ:GRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GRI Bio Inc
Net Income
GRI Bio Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GRI Bio Inc
NASDAQ:GRI
|
Net Income
-$12m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income
$26.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
GRI Bio Inc
Glance View
GRI Bio Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in La Jolla, California and currently employs 2 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biotechnology company. The firm is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The firm's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company’s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need.
See Also
What is GRI Bio Inc's Net Income?
Net Income
-12m
USD
Based on the financial report for Dec 31, 2025, GRI Bio Inc's Net Income amounts to -12m USD.
What is GRI Bio Inc's Net Income growth rate?
Net Income CAGR 5Y
-20%
Over the last year, the Net Income growth was -46%. The average annual Net Income growth rates for GRI Bio Inc have been -19% over the past three years , -20% over the past five years .
